Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Nurix Therapeutics (NRIX) Leases (2021 - 2025)

Nurix Therapeutics (NRIX) has disclosed Leases for 5 consecutive years, with $50.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Leases rose 79.53% to $50.5 million in Q4 2025 year-over-year; TTM through Nov 2025 was $50.5 million, a 79.53% increase, with the full-year FY2025 number at $50.5 million, up 79.53% from a year prior.
  • Leases was $50.5 million for Q4 2025 at Nurix Therapeutics, down from $53.0 million in the prior quarter.
  • In the past five years, Leases ranged from a high of $53.0 million in Q3 2025 to a low of $5.8 million in Q2 2025.
  • A 5-year average of $22.4 million and a median of $15.9 million in 2022 define the central range for Leases.
  • Peak YoY movement for Leases: skyrocketed 200.02% in 2024, then tumbled 79.89% in 2025.
  • Nurix Therapeutics' Leases stood at $14.0 million in 2021, then decreased by 11.85% to $12.3 million in 2022, then surged by 152.26% to $31.1 million in 2023, then fell by 9.64% to $28.1 million in 2024, then skyrocketed by 79.53% to $50.5 million in 2025.
  • Per Business Quant, the three most recent readings for NRIX's Leases are $50.5 million (Q4 2025), $53.0 million (Q3 2025), and $5.8 million (Q2 2025).